News

What’s new at Myllia — announcements, publications and partnerships from our CRISPR screening team in Vienna.

Meet the speaker #6 | Perturb 2027

Professor at UCSF and a Core Investigator at the Arc Institute, get to know more about Dr. Gilbert, an early pioneer in repurposed CRISPR systems that are used to turn genes on and off (CRISPRa/i and CRISPRoff/on).

Meet the speaker #5 | Perturb 2027

Director of the Gladstone-UCSF Institute of Genomic Immunology and Professor in the UCSF Department of Medicine, get to know more about Dr. Marson’s research with genetically modified T cells.

Myllia announces newly formed board with industry leaders

Single-cell commercial leader Simone Günther, US biotech veteran Sandy Zweifach, and Werner Lanthaler (Wlanholding) join to guide Myllia's next phase of growth

Meet the speaker #4 | Perturb 2027

With a career that spans UCSF, MIT and Gladstones Institutes, get to know more about Dr. Christina Theodoris’s career and research with AI models focused on understanding gene network dynamics.

Meet the speaker #3 | Perturb 2027

Associate Professor at Stanford University, get to know Dr. Anshul Kundaje and learn about his research with machine learning models of gene regulation.

Meet the speaker #2 | Perturb 2027

Earning his PhD from the University of Washington, Dr. Junyue Cao went on to lead the Laboratory of Single-Cell Genomics and Population Dynamics at The Rockefeller University. Learn more about his career path.

Meet the speaker #1 | Perturb 2027

With a career that includes directing the Icahn Genomics Institute and vice-chairing the Department of Immunology & Immunotherapy at the Mount Sinai Medical Center, get to know more about Dr. Brian Brown's career.

Press Release: The State Model Publication in Cell 2026

A Landmark State Model Publication in Cell Positions Myllia Biotechnology as the Go-To Partner for Perturb-Seq Datasets in Primary Human Cells

Myllia launches image-based CRISPR screening for spatial target discovery

Element Biosciences and Myllia Biotechnology demonstrate successful multimodal optical pooled screening for drug discovery

Press Release: Myllia launches “VISTA”, the macrophage and dendritic cell screening platform

The breakthrough VISTA™ platform opens new frontiers in drug target discovery and leverages sequencing technology from Ultima Genomics.